Financhill
Sell
36

NBY Quote, Financials, Valuation and Earnings

Last price:
$0.57
Seasonality move :
-3.33%
Day range:
$0.55 - $0.57
52-week range:
$0.36 - $4.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.16x
P/B ratio:
0.52x
Volume:
52.9K
Avg. volume:
40.9K
1-year change:
-90.32%
Market cap:
$3.2M
Revenue:
$9.8M
EPS (TTM):
-$0.80

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
ATNM
Actinium Pharmaceuticals
-- -$0.28 -100% -7.24% $5.00
MTNB
Matinas BioPharma Holdings
-- -$0.78 -100% -45.83% --
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NBY
NovaBay Pharmaceuticals
$0.55 $0.85 $3.2M -- $0.00 0% 0.16x
ATNM
Actinium Pharmaceuticals
$1.58 $5.00 $49.3M -- $0.00 0% --
MTNB
Matinas BioPharma Holdings
$0.86 -- $4.4M -- $0.00 0% 1.02x
NNVC
Nanoviricides
$1.57 -- $25.2M -- $0.00 0% --
OGEN
Oragenics
$0.14 $1.00 $3M -- $0.00 0% 1.33x
TOVX
Theriva Biologics
$0.45 $7.00 $3.7M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
ATNM
Actinium Pharmaceuticals
-- -3.541 -- 9.03x
MTNB
Matinas BioPharma Holdings
-- 1.451 -- --
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
MTNB
Matinas BioPharma Holdings
-- -$1.9M -- -- -- -$2M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

NovaBay Pharmaceuticals vs. Competitors

  • Which has Higher Returns NBY or ATNM?

    Actinium Pharmaceuticals has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of -11511.11%. NovaBay Pharmaceuticals's return on equity of -461.38% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About NBY or ATNM?

    NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 53.85%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 216.46%. Given that Actinium Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Actinium Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NBY
    NovaBay Pharmaceuticals
    1 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is NBY or ATNM More Risky?

    NovaBay Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.08% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.

  • Which is a Better Dividend Stock NBY or ATNM?

    NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NBY or ATNM?

    NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. NovaBay Pharmaceuticals's net income of $7.7M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns NBY or MTNB?

    Matinas BioPharma Holdings has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Matinas BioPharma Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
    MTNB
    Matinas BioPharma Holdings
    -- -$0.33 --
  • What do Analysts Say About NBY or MTNB?

    NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 53.85%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 3373.83%. Given that Matinas BioPharma Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NBY
    NovaBay Pharmaceuticals
    1 0 0
    MTNB
    Matinas BioPharma Holdings
    0 2 0
  • Is NBY or MTNB More Risky?

    NovaBay Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.08% less volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.261%.

  • Which is a Better Dividend Stock NBY or MTNB?

    NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NBY or MTNB?

    NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Matinas BioPharma Holdings quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Matinas BioPharma Holdings's net income of -$1.7M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus 1.02x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
    MTNB
    Matinas BioPharma Holdings
    1.02x -- -- -$1.7M
  • Which has Higher Returns NBY or NNVC?

    Nanoviricides has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About NBY or NNVC?

    NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 53.85%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 314.01%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NBY
    NovaBay Pharmaceuticals
    1 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is NBY or NNVC More Risky?

    NovaBay Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.08% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock NBY or NNVC?

    NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NBY or NNVC?

    NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Nanoviricides's net income of -$2.2M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns NBY or OGEN?

    Oragenics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About NBY or OGEN?

    NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 53.85%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 620.98%. Given that Oragenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Oragenics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NBY
    NovaBay Pharmaceuticals
    1 0 0
    OGEN
    Oragenics
    0 1 0
  • Is NBY or OGEN More Risky?

    NovaBay Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.08% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock NBY or OGEN?

    NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NBY or OGEN?

    NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Oragenics's net income of -$2.2M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus 1.33x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
    OGEN
    Oragenics
    1.33x -- -- -$2.2M
  • Which has Higher Returns NBY or TOVX?

    Theriva Biologics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About NBY or TOVX?

    NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 53.85%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1448.67%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    NBY
    NovaBay Pharmaceuticals
    1 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is NBY or TOVX More Risky?

    NovaBay Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.08% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock NBY or TOVX?

    NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NBY or TOVX?

    NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Theriva Biologics's net income of -$4.3M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Dell Stock Be in 5 Years?
Where Will Dell Stock Be in 5 Years?

So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
70
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 47x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 30

SharpLink Gaming [SBET] is up 0.52% over the past day.

Buy
55
RGC alert for May 30

Regencell Bioscience Holdings [RGC] is up 12.69% over the past day.

Buy
73
CTEV alert for May 30

Claritev [CTEV] is up 6.48% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock